Atrium Health Levine Cancer | Strategic Alliance Partners

Peter Voorhees, MD, discusses the FDA approval of daratumumab for patients with high-risk smoldering multiple myeloma.

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

Neelam V. Desai, MD, discusses the role of first-line CDK4/6 inhibitors in HR-positive, HER2-negative and HER2-positive metastatic breast cancer.

Antoinette Tan, MD, MHS, discusses the safety profiles of ADCs and ADC selection considerations for breast cancer.

Antoinette Tan, MD, MHS, discusses the implications of the DESTINY-Breast06 trial of T-DXd vs chemotherapy in HER2-low or -ultralow breast cancer.

Peter Voorhees, MD, highlights 5-year follow-up data from the CARTITUDE-1 trial evaluating cilta-cel in relapsed/refractory multiple myeloma.

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

Arielle Heeke, MD, highlights the role of adjuvant abemaciclib and ribociclib in patients with HR-positive, HER2-negative, early breast cancer.

Michael R. Grunwald, MD, discusses the importance of monitoring risk factors associated with disease progression in patients with polycythemia vera.

Atrium Health Levine Cancer will begin treating patients with proton beam therapy.

Fixed-duration ibrutinib plus venetoclax generated meaningful survival benefits and durable responses in high-risk subgroups of patients with CLL/SLL.

Michael R. Grunwald, MD, FACP, discusses the characteristics of patients with polycythemia vera enrolled in the REVEAL study and limitations of the study.

The panel concludes its discussion with a look at the future of AYA ALL treatment and the role of clinical trials and innovative therapies in improving outcomes for patients.

Experts on AYA ALL discuss the potential applicability of modified treatment regimens and the importance of multidisciplinary collaboration to meet the unique needs of patients.

A panel of experts discusses the use of CALBG 10403 in patients with AYA ALL, highlighting adverse events reported with the regimen and mitigation practices.

Michael Grunwald, MD, presents the case of a 32-year-old woman with AYA ALL, and Kelly Weaver, NP, DNP, discusses the role of cytogenetics in diagnosing patients with AYA ALL.

Experts on acute lymphoblastic leukemia discuss administration practices for asparaginase erwinia chrysanthemi and the importance of timely referrals and coordination of care.

Kelly Weaver, NP, DNP, and Grace Elsey, PharmD, outline adverse effects associated with asparaginase erwinia chrysanthemi in patients with ALL and actions that can be taken to mitigate them.

Michael R. Grunwald, MD, discusses findings from a real-world study of risk factors related to disease progression in polycythemia vera.

Grace Elsey, PharmD, discusses the trial that led to the approval of asparaginase erwinia chrysanthemi and how it impacts AYA ALL treatment paradigms.

Focusing on the current treatment landscape for patients with AYA ALL, the panel discusses clinical practices and treatment decisions based on age.

Experts on acute lymphoblastic leukemia share their clinical experiences, describe high-risk features, and provide insights on risk stratification practices.

A panel of experts from Atrium Health Levine Cancer Institute present a patient case and provide an overview of adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL).

Vaidehi Mujumdar, MD, discusses several key trials that have helped shift the ovarian cancer treatment paradigm.

Michael R. Grunwald, MD, FACP, discusses disease progression in patients with low-risk myelofibrosis enrolled in the prospective MOST study.

Over a 4-year period, most patients with lower-risk myelofibrosis experienced disease progression, according to the prospective MOST study.

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

Dr Brown discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer.

Jubilee Brown, MD, highlights the RAS/MAPK pathway in low-grade serous ovarian cancer and research with avutometinib/defactinib that prompted RAMP 301.

Vaidehi Mujumdar, MD, discusses how awareness initiatives can help address unmet needs in patients with ovarian cancer on World Ovarian Cancer Day.